CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-03 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,026 | 324,524 | ||
| 2023-09-29 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2023-09-29 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −12,000 | $13.62 | $163K | 0 |
| 2023-09-29 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 332,550 | ||
| 2023-09-26 | 5AM Partners VI, LLC 10% owner | Sale | −164,789 | $15.00 | $2.5M | 4,306,179 |
| 2023-09-26 | 5AM Partners VI, LLC 10% owner | Sale | −32,711 | $15.00 | $491K | 854,796 |
| 2023-09-25 | Kintz Samuel President and CEO | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2023-09-25 | Kintz Samuel President and CEO | Sale 10b5-1 | −12,000 | $13.81 | $166K | 0 |
| 2023-09-25 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 332,550 | ||
| 2023-08-24 | 5AM Partners VI, LLC 10% owner | Sale | −367,124 | $16.00 | $5.9M | 4,470,968 |
| 2023-08-24 | 5AM Partners VI, LLC 10% owner | Sale | −72,876 | $16.00 | $1.2M | 887,507 |
| 2023-05-17 | ORBIMED ADVISORS LLC Director | Option exercise | +2,125 | $4.28 | $9K | 8,663,349 |
| 2023-05-17 | ORBIMED ADVISORS LLC Director | Option exercise · Stock Options (Right to Buy) | −2,125 | 0 | ||
| 2023-05-17 | Gupta Rishi Director | Option exercise | +2,125 | $4.28 | $9K | 8,663,349 |
| 2023-05-17 | Gupta Rishi Director | Option exercise · Stock Options (Right to Buy) | −2,125 | 0 | ||
| 2023-04-04 | Patel Anish Chief Operating Officer | Grant or award · Stock Option (right to buy) | +206,000 | 206,000 | ||
| 2023-04-04 | Lyssikatos Joseph P Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +206,000 | 206,000 | ||
| 2023-04-04 | Hohl Benjamin Chief Financial Officer | Grant or award · Stock Option (right to buy) | +206,000 | 206,000 | ||
| 2023-04-04 | Collins Helen Louise Chief Medical Officer | Grant or award · Stock Option (right to buy) | +206,000 | 206,000 | ||
| 2023-04-04 | Kintz Samuel President and CEO | Grant or award · Stock Option (right to buy) | +452,000 | 452,000 |
Page 30 of 37 · 724 trades